Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global brain hemorrhage therapeutics market. The report identifies the key trends shaping and driving the global brain hemorrhage therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global brain hemorrhage therapeutics market was worth $358m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 3% to $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to its stable prevalence, a high mortality rate and a weak pipeline of only two company sponsored drugs. The main risk factors associated with brain hemorrhage are lifestyle factors such as smoking, obesity and alcohol consumption. The most common therapies are prescribed off-label, such as anti-hypertensive agents (labetalol and nicardipine), hemostatic agents (vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy (mannitol 20%) which provide symptomatic treatment but lack superior safety and efficacy. The market does not have any approved therapies. These factors will result in the slow growth of the global brain hemorrhage therapeutics market to 2018.

GlobalData has found that the brain hemorrhage therapeutics market has high unmet needs, suggesting that the current market is not well served by the current treatment options. Moreover, these treatment options are not approved and are used as off-label. The market is dominated by off-label and generic medications which include antihypertensive agents, hemostatic agents, antiepileptic agents, and osmotherapy. Absence of approved therapies for brain hemorrhage clearly establishes that the current brain hemorrhage therapeutics market has high unmet need and there is scope for new entrants exhibiting superior safety and efficacy.

Scope

The report provides information on the key drivers and challenges of the brain hemorrhage therapeutics market. Its scope includes -

• Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) brain hemorrhage market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Most of the clinical trials are conducted by academic institutions, currently only GLP-1 CellBeads and PG2 are the drugs sponsored by CellMed/BTG and PhytoHealth Corporation respectively. Of the total number drugs in the pipeline, four drugs are first-in-class and the remaining 12 drugs are generics. The mechanism of action of one drug in phase 0 is unknown. The first-in-class molecules have a distinct advantage over the currently marketed products with regards to better symptomatic management.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the brain hemorrhage therapeutics market.
• Analysis of key recent licensing and partnership agreements in brain hemorrhage therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global brain hemorrhage therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global brain hemorrhage therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global brain hemorrhage therapeutics market landscape? – Identify, understand and capitalize

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 BRAIN HEMORRHAGE THERAPEUTICS - INTRODUCTION

2.1 Overview
  2.1.1 Diagnostic and Statistical Manual of Cerebrovascular Diseases - Stroke Classification
  2.1.2 WHO Stroke Definition
  2.1.3 Quality of Life
2.2 Epidemiology
  2.2.1 Worldwide Prevalence
  2.2.2 Incidence of Cerebral Hemorrhage
  2.2.3 Epidemiology Trends
  2.2.4 Age, Gender and Ethnicity
  2.2.5 Economic Burden
2.3 Etiology and Pathophysiology
  2.3.1 ICH
  2.3.2 SAH
  2.3.3 Risk Factors
2.4 Signs and Symptoms
  2.4.1 The Face Arm Speech Test
2.5 Diagnosis
  2.5.1 Other Tests
  2.5.2 The Glasgow Coma Scale
  2.5.3 Referral Pathway
2.6 Treatment and Management
  2.6.1 Emergency Management
  2.6.2 Prevention
  2.6.3 Rehabilitation
2.7 GlobalData Pipeline Report Guidance

3 BRAIN HEMORRHAGETHERAPEUTICS - MARKET CHARACTERIZATION

3.1 Overview
3.2 Brain Hemorrhage Therapeutics Market Size (2005 - 2010) - Global
3.3 Brain HemorrhageTherapeutics Market Forecast (2010-2018) - Global
3.4 Brain Hemorrhage Therapeutics Market Size (2005-2010) - The US
3.5 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - The US
3.6 Brain Hemorrhage Therapeutics Market Size (2005-2010) - France
3.7 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - France
3.8 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Germany
3.9 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Germany
3.10 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Italy
3.11 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Italy
3.12 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Spain
3.13 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Spain
3.14 Brain Hemorrhage Therapeutics Market Size (2005-2010) - The UK
3.15 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - The UK
3.16 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Japan
3.17 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Japan
3.18 Drivers and Barriers for the Brain Hemorrhage Therapeutics Market
  3.18.1 Drivers for the Brain Hemorrhage Therapeutics Market
  3.18.2 Barriers for the Brain Hemorrhage Therapeutics Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway

4 BRAIN HEMORRHAGETHERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Off-Label Marketed Products in the Brain Hemorrhage Market
  4.3.1 Antihypertensive
  4.3.2 Hemostatic Therapy
  4.3.3 Antiepileptic Drugs
  4.3.4 Osmotherapy
4.4 Key Takeaway

5 BRAIN HEMORRHAGE THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Brain Hemorrhage Therapeutics Pipeline - Pipeline by Phases of Development
  5.3.1 Brain Hemorrhage Therapeutics - Phase III Pipeline
  5.3.2 Brain Hemorrhage Therapeutics - Phase II Pipeline
  5.3.3 Brain Hemorrhage Therapeutics - Phase I/II Pipeline
  5.3.4 Brain Hemorrhage Therapeutics - Phase I Pipeline
  5.3.5 Brain Hemorrhage Therapeutics - Phase 0 Pipeline
5.4 Brain Hemorrhage Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Brain Hemorrhage Therapeutics - Promising Drugs Under Development
5.7 Molecule Profile for Promising Drugs Under Development
  5.7.1 GLP-1 CellBeads
5.8 Key Takeaway

6 BRAIN HEMORRHAGE THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Brain Hemorrhage Therapeutics Clinical Trials

7 BRAIN HEMORRHAGETHERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario

8 BRAIN HEMORRHAGETHERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 BTG
  8.2.1 Company Overview
  8.2.2 Financial Overview
  8.2.3 Business Description
  8.2.4 Brain Hemorrhage Therapeutics Pipeline

9 BRAIN HEMORRHAGE THERAPEUTICS MARKET - APPENDIX

9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
  9.3.1 Coverage
  9.3.2 Secondary Research
  9.3.3 Forecasting
  9.3.4 Primary Research
  9.3.5 Expert Panels
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

LIST OF TABLES

Table 1: Stroke and Stroke Risk Factors using International Classification of Diseases, Revisions 9 and 10
Table 2: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases, The US, 2010
Table 3: Economic Burden of Stroke
Table 4: Intravenous Antihypertensive Agents for Acute Intracerebral Hemorrhage
Table 5: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2005-2010
Table 6: Brain Hemorrhage Therapeutics, Global, Revenue Forecasts ($m), 2010-2018
Table 7: Brain HemorrhageTherapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 8: Brain Hemorrhage Therapeutics Market, The US, Revenue ($m),2010-2018
Table 9: Brain Hemorrhage Therapeutics, France, Market Revenue ($m), 2005-2010
Table 10: Brain Hemorrhage Therapeutics, France, Revenue Forecasts ($m), 2010-2018
Table 11: Brain Hemorrhage Therapeutics, Germany, Market Revenue ($m), 2005-2010
Table 12: Brain Hemorrhage Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Table 13: Brain Hemorrhage Therapeutics, Italy, Market Revenue ($m), 2005-2010
Table 14: Brain Hemorrhage Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Table 15: Brain Hemorrhage Therapeutics, Spain, Market Revenue ($m), 2005-2010
Table 16: Brain Hemorrhage Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Table 17: Brain Hemorrhage Therapeutics, The UK, Market Revenue ($m), 2005-2010
Table 18: Brain Hemorrhage Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018
Table 19: Brain Hemorrhage Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 20: Brain Hemorrhage Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 21: Brain Hemorrhage Therapeutics - Phase III Pipeline, 2011
Table 22: Brain Hemorrhage Therapeutics - Phase II Pipeline, 2011
Table 23: Brain HemorrhageTherapeutics - Phase I Pipeline, 2011
Table 24: Brain HemorrhageTherapeutics- Preclinical Pipeline, 2011
Table 25: Brain HemorrhageTherapeutics- Phase 0 Pipeline, 2011
Table 26: Brain Hemorrhage Therapeutics - Most Promising Drugs Under Development, 2011
Table 27: Brain Hemorrhage Therapeutics - Clinical Trials by Country, 2011
Table 28: Brain Hemorrhage Therapeutics - Clinical Trials by Phase, 2011
Table 29: Brain Hemorrhage Therapeutics - Clinical Trials by Status, 2011
Table 30: Brain Hemorrhage Therapeutics - Prominent Sponsors, 2011
Table 31: Brain Hemorrhage Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 32: BTG - Brain Hemorrhage Therapeutics Pipeline Products, 2011

LIST OF FIGURES

Figure 1: Physiological Difference between Acute Ischemic Stroke and Hemorrhagic Stroke
Figure 2: Stroke Compared with Other Causes of Death
Figure 3: Burst and Breaks: Causes of Hemorrhagic Stroke
Figure 4: Worldwide Prevalence of Stroke
Figure 5: Percentage Breakdown of Direct Costs after Stroke
Figure 6: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases, The US, 2010
Figure 7: Computerized Tomography (CT) Images of the Common Sites of Intracerebral Hemorrhage Attributed to Hypertension
Figure 8: Subarachnoid Hemorrhage Caused by Ruptured Aneurysm
Figure 9: Stroke Risk Scorecard
Figure 10: The Face Arm Speech Test
Figure 11: The Glasgow Coma Scale
Figure 12: Referral Pathway for Brain Hemorrhage
Figure 13: Treatment Algorithm for Cerebral Hemorrhage
Figure 14: Treatment Stages for Brain Hemorrhage
Figure 15: Emergency Management Algorithm for Patients with Intracerebral Hemorrhage
Figure 16: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2005-2010
Figure 17: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2010-2018
Figure 18: Brain HemorrhageTherapeutics Market, The US, Revenue ($m), 2005-2010
Figure 19: Brain Hemorrhage Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 20: Brain Hemorrhage Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 21: Brain Hemorrhage Therapeutics, France, Revenue Forecasts ($m), 2010-2018
Figure 22: Brain Hemorrhage Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 23: Brain Hemorrhage Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Figure 24: Brain Hemorrhage Therapeutics, Italy, Market Revenue ($m), 2005-2010
Figure 25: Brain Hemorrhage Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Figure 26: Brain Hemorrhage Therapeutics, Spain, Market Revenue ($m), 2005-2010
Figure 27: Brain Hemorrhage Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Figure 28: Brain Hemorrhage Therapeutics, The UK, Market Revenue ($m), 2005-2010
Figure 29: Brain Hemorrhage Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018
Figure 30: Brain Hemorrhage Therapeutics, Japan, Market Revenue ($m), 2005-2010
Figure 31: Brain Hemorrhage Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 32: Opportunity and Unmet Need in the Brain Hemorrhage Therapeutics Market, 2010
Figure 33: Brain Hemorrhage Therapeutics, Strategic Competitor Assessment, 2010
Figure 34: Brain Hemorrhage Therapeutics - Pipeline by Phase of Development, 2011
Figure 35: Brain Hemorrhage Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 36: Brain Hemorrhage Therapeutics - Technology Trends Analytics Framework, 2011
Figure 37: Brain Hemorrhage Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 38: Brain Hemorrhage Therapeutics - Clinical Trials by Region, 2011
Figure 39: Brain Hemorrhage Therapeutics - Clinical Trials by Phase, 2011
Figure 40: Brain Hemorrhage Therapeutics - Clinical Trials by Status, 2011
Figure 41: Brain Hemorrhage Therapeutics - Overall Sponsors, 2011
Figure 42: Brain Hemorrhage Therapeutics - Prominent Sponsors, 2011
Figure 43: Brain Hemorrhage Therapeutic - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 44: Brain Hemorrhage Therapeutics, Key Events Impacting Future Market
Figure 45: Brain Hemorrhage Therapeutics, Strategic Assessment, 2011
Figure 46: Brain Hemorrhage Therapeutics, Clinical Pipeline by Company, 2011
Figure 47: GlobalData Market Forecasting Model

COMPANIES MENTIONED

BTG Skip to top